|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:age
|
6 months and older
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
gptkb:J07BX03
|
|
gptkbp:boosterEfficacy
|
high against severe disease
|
|
gptkbp:boosters
|
yes
|
|
gptkbp:brand
|
gptkb:Spikevax
|
|
gptkbp:CDCCode
|
91318
91301
91320
91316
91306
91313
91314
91315
91317
91319
|
|
gptkbp:clinicalTrialPhase
|
July 2020 - November 2020
|
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Moderna
gptkb:National_Institute_of_Allergy_and_Infectious_Diseases
|
|
gptkbp:dosageSchedule
|
two doses, 28 days apart
|
|
gptkbp:emergencyServices
|
December 2020
|
|
gptkbp:firstDoseEfficacy
|
~80%
|
|
gptkbp:fullApprovalDate
|
January 31, 2022
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Moderna COVID-19 Vaccine
|
|
gptkbp:lactationUse
|
allowed
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mainIngredient
|
sodium chloride
acetic acid
sucrose
lipid nanoparticles
mRNA encoding SARS-CoV-2 spike protein
water for injection
sodium acetate
tromethamine
|
|
gptkbp:patent
|
gptkb:Moderna
|
|
gptkbp:pregnancyCategory
|
consult healthcare provider
allowed with medical advice
|
|
gptkbp:rareSideEffects
|
anaphylaxis
myocarditis
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:secondDoseEfficacy
|
~94%
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
muscle pain
chills
pain at injection site
|
|
gptkbp:storage
|
-25°C to -15°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
messenger RNA
|
|
gptkbp:UNII
|
QDW8MXH2FS
|
|
gptkbp:WHOEmergencyUseListing
|
April 30, 2021
|
|
gptkbp:bfsParent
|
gptkb:Spikevax
gptkb:mRNA-1273
gptkb:вспышка_COVID-19
|
|
gptkbp:bfsLayer
|
5
|